Article Sidebar

PDF
Date Published: 11/07/2022
Online Published: 11/07/2022
Abstract Views: 158
Views PDF: 99
DOI: https://doi.org/10.55046/vjrnm.26.461.2016
Issue
No. 26 (2016)
Section
Scientific research
How to Cite
Truong, T. T., Pham, M. T., Ngo, L. L., Trinh, H. C., Vu, D. L., Mai , T. K., Tran, D. H., & Tran, H. B. (2022). The results of Y90 radioembolization in treatment of hepatocellular carcinoma. Vietnamese Journal of Radiology and Nuclear Medicine, 26, 59-65. https://doi.org/10.55046/vjrnm.26.461.2016

The results of Y90 radioembolization in treatment of hepatocellular carcinoma

Dr Truong Thi Thanh1, professor Pham Minh Thong1, Dr Ngo Le Lam1, Dr Trinh Ha Chau1, Dr Vu Dang Luu1, Dr Mai Trong Khoa1, Dr Tran Dinh Ha1, Dr Tran Hai Binh1
1 Department of Diagnostic Imaging - Bach Mai Hospital

Main Article Content

Abstract

Background: Hepatocellular carcinoma (HCC) is aggressive primary malignancy of the liver that most commonly presents late
in the disease course. As a result, the majority of patients are not candidates for curative therapies. Locoregional therapies
including Yttrium-90 (Y-90) radioembolization play an important role in management of the vast majority of patients with HCC.
Methods: Patients with unnresectable HCC (n=41) treated with Y-90 radioembolization from 2013 to 2016 were evaluated
retrospectively. Data was abstracted from medical records including patient charts, laboratory data, and imaging.
Results: The most common clinical toxicity among all patients was fatigue (58.5%). A clinical benefit, defined as patients
achieving PR was seen in 95.13% of cases; was seen complete reponse (CR) in 4.87%. The mean overall survival from the time
of diagnosis was 18.4 months.
Conclutions: For patients with HCC, Y-90 radioembolization is a safe and well-tolerated procedure. Our experience suggests
that a significant percentage of patients achieve clinical benefit including many with PR. Prospective, randomized data is required to compare radioembolization with other therapies including chemoembolization and systemic therapy with sorafenib.

Article Details

Keywords

Radioembolization, Yttrium-90 microspheres, SIR-spheres, Hepatocellular carcinoma, Transarterial radioembolization, SIRT

References

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-5.
3. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long- term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.
4. Lewandowski RJ, Salem R. Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver. Semin Intervent Radiol
2006;23:64-72.
5. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205-13.
6. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med 2000;41:1673-81.
7. D’Avola et al (2009) “A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma”, Hepato-gastroenterology; 56: 1683-1688.
8. Sangro B et al (2013) “Prognostic Factors and Prevention of Radioembolization-Induced Liver Disease”, Hepatology 2013; 57:1078-1087.